TL/DR –
The Trump administration plans to conclude a temporary subsidy program that has helped mitigate Medicare prescription drug coverage costs for millions of older adults, potentially leading to higher costs in 2027. The Centers for Medicare & Medicaid Services (CMS) initially implemented the program in 2024 to lower Medicare Part D prescription drug costs in response to the 2022 Inflation Reduction Act. While CMS insists the impact on beneficiaries will be minimal, critics argue the move contributes to increasing healthcare costs, with the expiration of the program coinciding with a high-stakes midterm election year.
Medicare Drug Cover Subsidy Program to End, Affecting Premiums of Older Adults
After enjoying two years of offset premium payments, millions of elderly Americans depending on Medicare prescription drug coverage could face an increase in monthly costs starting 2027. This comes as the Trump administration announces the conclusion of a temporary subsidy program.
The subsidy program, which has been overseen by The Centers for Medicare & Medicaid Services (CMS), was introduced in 2024 by the Biden administration. The program aimed at reducing Medicare Part D prescription drug costs for patients, in response to the 2022 Inflation Reduction Act.
Political Impact and Beneficiary Concerns
Though federal officials maintain that the financial impact on Medicare beneficiaries will be small, this announcement presents potential political backlash for the Republican-led administration, especially as the country braces for a high-stakes midterm election year. Cost of living is a primary concern for voters, and with a significant number of older adults, who frequently vote, surviving on fixed incomes, every dollar is crucial. The approximate 25 million Americans under Medicare Part D plans will be informed about the 2027 rates when they cast their votes in the November elections.
Democrats have pointed out the decision by CMS as a consistent attack on healthcare affordability, alongside the expiration of Affordable Care Act subsidies and federal Medicaid cuts, which had previously reduced premium costs for working Americans.
Senate Minority Leader Chuck Schumer reacted to the news by stating, “The Trump administration is actively raising prescription drug costs for 25 million seniors,”. He continued, “Heartless, cruel, and completely by choice.”
Financial Implications and Response from CMS
Commenting on the matter, CMS Administrator Dr. Mehmet Oz, claimed that terminating the subsidy program would save billions of taxpayer dollars that would otherwise go to insurance companies. He disclosed that the program had cost the agency approximately $3.6 billion in 2026.
Dr. Oz further explained that most Medicare beneficiaries would see a less than $10-per-month increase, and some could even experience lower premiums than before. He assured that “Every Medicare beneficiary still has access to low-cost plans, and we will continue to lower prescription drug prices for every American patient, from more MFN deals to our policy giving seniors access to GLP-1s for $50 a month,”.
Other Factors and Uncertainties
This week’s decision does not affect the out-of-pocket cap that limits the amount spent by older adults with standalone Medicare drug coverage on their prescription drugs throughout the year. The cap was set at $2,100 in 2026 but is expected to increase to $2,400 in 2027.
According to non-profit healthcare research organization KFF, with the subsidies, Part D beneficiaries paid an average monthly premium of $36 for their prescription drugs this year. The subsidies reduced the average premium by $16 in 2026, as indicated by the federal Medicare Payment Advisory Commission (MedPAC).
It remains uncertain how many Americans will be affected by this change and how much more they will have to pay. As CMS is expected to release information about next year’s premiums in September, older Americans will have the chance to shop for plans annually, and prices will continue to vary widely among them.
AARP Executive Vice President Nancy LeaMond expressed support for the temporary subsidy, saying, “While it’s too early to know the full impact of this change, it would be unfortunate if this decision made Part D coverage less affordable, just as we’re beginning to see billions in savings from Medicare drug price negotiation,”.
Juliette Cubanski, vice president and director of the program on Medicare policy at KFF, remarked that despite the price increases being marginal for some consumers, they could be impactful for others, especially when coupled with rising costs in other areas such as groceries, gas, and housing. She predicted, “What’s going to matter most for consumers is how much more or less they have to pay at the end of a month, and how much they have left after the bills are paid,” and added, “This could just make it more challenging for some people to make that math work.”
—
Read More US Economic News